GDTC
CytoMed Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · SG
$0.86
−2.15%Year over year
Reported trailing growth
- Revenue
- +69.5%
- EBITDA
- —
- EBIT
- -8.4%
- EPS
- -35.8%
- Free cash flow
- -76.6%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.4%
- EBITDA
- —
- EBIT
- -44.4%
- Net income
- -55.6%
- EPS
- -50.0%
- Free cash flow
- -7.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025